文献速递肝病

在961例接受直接抗病毒药物治疗的慢性丙型肝炎患者美国队列中PROMIS简表测量的心理测量学特性

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-29

分析美国11家肝病中心961例启动直接抗病毒治疗的慢性丙型肝炎患者治疗前数据,评估10种PROMIS量表与HIT-6的信度与效度。HIT-6和多数PROMIS量表信度优秀(α≥0.87),天花板效应少见(<4%),30%-59%患者无报告症状(地板效应),与理论相似条目的相关为0.39-0.77,支持结构效度与已知组效度。

要点

  • HIT-6与多数PROMIS量表信度优秀,Cronbach's α≥0.87。
  • 天花板效应少见(<4%),30%-59%患者报告无症状(地板效应)。
  • PROMIS量表与HCV-PRO和MSAS理论相似条目呈中度至强相关(0.39-0.77)。

核心结论

  • HIT-6与PROMIS量表在961例启动直接抗病毒治疗的慢性丙型肝炎患者中心理测量学特性表现满意。
  • 原文指出这些患者报告结局工具仍有进一步优化的空间。
  • 原文提出需要评估其随时间变化的表现以及在代表性不足亚组中的表现。

研究设计与样本

  • 分析美国11家肝病中心961例启动直接抗病毒治疗的慢性丙型肝炎患者治疗前数据。
  • 采用Cronbach's α系数评估内部信度,并检查频数分布的地板与天花板效应。
  • 通过条目反应理论模型考察结构效度,采用与HCV-PRO和MSAS理论相似条目的相关性评估聚合效度。
  • 通过观察不同肝病状态与合并症数量下的患者报告结局差异考察已知组效度。

主要发现

  • HIT-6和多数PROMIS量表信度优秀,Cronbach's α≥0.87。
  • 天花板效应少见(<4%),30%-59%的患者报告无任何症状(地板效应)。
  • 数据支持HIT-6和多数PROMIS量表的结构效度。
  • PROMIS量表与HCV-PRO和MSAS理论相似条目呈中度至强相关(0.39-0.77)。
  • 观察到更差的患者报告结局评分与晚期肝硬化和更多合并症数量之间的趋势,支持已知组效度。

关键数值与推荐

  • HIT-6和多数PROMIS量表Cronbach's α≥0.87。
  • 天花板效应<4%,地板效应见于30%-59%的患者。
  • PROMIS量表与HCV-PRO和MSAS理论相似条目的相关系数为0.39-0.77。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出需要评估这些患者报告结局工具随时间变化的表现。
  • 原文指出需要在代表性不足的亚组中评估其表现。
  • 原文指出这些患者报告结局工具仍有进一步优化的空间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To better understand symptoms experienced by patients infected with chronic hepatitis C virus (HCV), valid and reliable patient-reported outcome (PRO) measures are needed. AIM: To assess the reliability and validity of 10 patient-reported outcomes measurement information system (PROMIS) measures and the Headache Impact Test-6 (HIT-6) in a large national sample of patients with HCV. METHODS: Pre-treatment data from 961 patients with HCV starting direct acting antiviral therapy at 11 U.S. liver centers were analyzed. Internal reliability was evaluated using Cronbach's alpha coefficient; frequency distributions were examined for floor and ceiling effects; structural validity was investigated via item-response-theory models; convergent validity was evaluated using correlations with theoretically-similar items from the HCV-PRO and memorial symptom assessment scale (MSAS); and known-groups validity was investigated by observing PRO differences by liver disease status and number of comorbidities. RESULTS: The HIT-6 and the majority of the PROMIS measures yielded excellent reliability (alphas ≥ 0.87). Ceiling effects were infrequent ( < 4%), while 30%-59% of patients reported no symptoms (floor effects). The data supported structural validity of the HIT-6 and most PROMIS measures. The PROMIS measures showed moderate to strong correlations with theoretically-similar items from the HCV-PRO and MSAS (0.39-0.77). Trends were observed between worse PRO scores and advanced cirrhosis and greater number of comorbidities, lending support for known-groups validity. CONCLUSIONS: The psychometric properties of the HIT-6 and PROMIS measures performed satisfactorily in this large cohort of patients with HCV starting direct acting antiviral therapy. Opportunities exist for further refinement of these PROs. Evaluation of performance over time and in under-represented subgroups is needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Evon DM, Amador J, Stewart P, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018. PMID: 29377191. doi:10.1111/apt.14531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。